CareDx, Inc. (NASDAQ:CDNA) Given Consensus Rating of “Hold” by Analysts

CareDx, Inc. (NASDAQ:CDNA) has received an average recommendation of “Hold” from the nine research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $27.3333.

CDNA has been the subject of several analyst reports. Wells Fargo & Company raised their price target on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Craig Hallum lowered shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective on the stock. in a research note on Tuesday, January 6th. BTIG Research lifted their target price on shares of CareDx from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings lowered shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, February 27th. Finally, Wall Street Zen cut shares of CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th.

Insider Activity at CareDx

In related news, CEO John Walter Hanna, Jr. sold 19,280 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the sale, the chief executive officer owned 597,405 shares of the company’s stock, valued at $12,641,089.80. This trade represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 29,636 shares of company stock worth $625,949. 4.40% of the stock is owned by corporate insiders.

Institutional Trading of CareDx

Several large investors have recently modified their holdings of the stock. Quarry LP bought a new stake in CareDx in the fourth quarter valued at $25,000. FNY Investment Advisers LLC acquired a new stake in shares of CareDx in the 3rd quarter valued at about $31,000. Allworth Financial LP bought a new stake in CareDx in the 2nd quarter valued at about $40,000. State of Alaska Department of Revenue bought a new position in CareDx in the third quarter worth approximately $43,000. Finally, Meeder Asset Management Inc. acquired a new stake in CareDx in the fourth quarter valued at approximately $79,000.

CareDx Trading Down 4.6%

NASDAQ CDNA opened at $17.89 on Friday. The firm has a market capitalization of $916.33 million, a PE ratio of -44.73 and a beta of 2.52. The business’s 50-day moving average price is $19.53 and its two-hundred day moving average price is $17.04. CareDx has a 12 month low of $10.96 and a 12 month high of $21.49.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). CareDx had a negative return on equity of 6.50% and a negative net margin of 5.65%.The company had revenue of $108.39 million for the quarter, compared to the consensus estimate of $102.76 million. During the same quarter last year, the business earned $0.18 earnings per share. CareDx’s revenue was up 25.2% compared to the same quarter last year. As a group, analysts forecast that CareDx will post -0.9 earnings per share for the current fiscal year.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.